Contact information
Type
Scientific
Primary contact
Mr Sadaquate Khan
ORCID ID
Contact details
Frenchay Hospital
Frenchay Park Road
Bristol
BS16 1LE
United Kingdom
+44 117 41 49330
sadaquate.khan@nbt.nhs.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
4455
Study information
Scientific title
Deep brain stimulation of the pedunculopontine nucleus for Parkinson's Disease: a single centre randomised interventional treatment trial
Acronym
Study hypothesis
In patients with Parkinson's disease problems with balance, walking and speech are considered to be some of the most disabling symptoms. The symptoms are collectively known as axial symptoms. At present the available medical therapy and surgery, in the form of deep brain stimulation result in a limited improvement in axial symptoms especially in the later stages of this disease. Research work over the past 20 years has indicated that degeneration of an area in the brainstem, the pedunculopontine nucleus (PPN) may be involved in producing axial symptoms in Parkinson's disease. Work by Professor Aziz in Oxford has shown an improvement in axial symptoms in primate models of Parkinson's disease following stimulation of the PPN.
Following on from this work, our research group was one of the first to publish on deep brain stimulation of this area in patients with Parkinson's Disease. Our initial results have shown a significant improvement of not only axial symptoms but patients also reported improvement in other symptoms including appetite and concentration. Following the success of our early pilot cases we now intend to perform a formalised trial in order to:
1. Determine the safety and efficacy of deep brain stimulation of the pedunculopontine nucleus (PPN) in conjunction with stimulation of the caudal zona incerta (cZi) (conventional site of stimulation in Parkinson's Disease) in patients with medically refractory Parkinson's Disease who have predominant symptoms of postural instability and gait dysfunction both in the on and off medication states)
2. Obtain greater understanding of the mechanism by which deep brain stimulation of the PPN and cZi region results in clinical improvement by studying the changes in regional cerebral blood flow using positron emission tomography (PET) scanning and electrical activity at these two sites using temporary externalised cables and electroencephalogram (EEG) readings from the scalp in the post-operative period whilst stimulating these two regions separately and in combination
Ethics approval
South West 5 REC, 28/04/2006, ref: 06/Q2007/20
Study design
Single centre randomised interventional treatment trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Topic: Dementias and Neurodegenerative Diseases Research Network; Subtopic: Parkinsons Disease; Disease: Parkinson's disease
Intervention
Following fully informed consent and surgical implantation of DBS electrodes to both the PPN and subthalamic region bilaterally, patients will enter into an initial 6 week period over which the Subthalamic region and PPN electrodes will be programmed individually and in combination in order to define the optimal settings for symptom control. At the end of the first 6 week period patients will be randomised into receiving deep brain stimulation at the predetermined optimal setting at either the Subthalamic region or the both the PPN and Subthalamic region simultaneously. This will occur for a further 6 - 12 week period at the end of which the primary and secondary outcome measures will be assessed. Following assessment of the outcome measures, patients will crossover to the other stimulator setting for a further 6 - 12 weeks. With two possible combinations of stimulator settings and an initial period used to define optimal stimulator settings the total duration of the trial will be 18 - 30 weeks.
Intervention type
Other
Phase
Phase II
Drug names
Primary outcome measures
Change in frequency of gait freezing, measured for 3 days in each condition and averaged.
Secondary outcome measures
1. Quality of life questionnaires (39-item Parkinson's Disease Questionnaire [PDQ-39] and 36-item Short Form Health Survey [SF-36])
2. The Unified Parkinson's Disease Rating Scale (UPDRS)
3. Change in concomitant antiparkinsonian medications
4. Neuropsychological assessment
5. Parkinson's Disease Non-Motor Symptoms Questionnaire
6. Timed walk, upper and lower limb movements and Purdue Pegboard
7. Tinetti balance and gait assessment tool
Measured pre-operatively and after each of the two randomisation settings (which could be at 12 - 18 weeks, or 18 - 30 weeks depending on how long the patient needs to be on each
stimulation setting in order to reach a stable clinical state on each of the stimulation settings.
Overall trial start date
22/10/2007
Overall trial end date
28/02/2011
Reason abandoned
Eligibility
Participant inclusion criteria
1. Diagnosis of advanced idiopathic Parkinson's disease poorly controlled on optimum medication with significant functional disability and predominant symptoms of postural instability and gait dysfunction in both the on and off medication states
2. They will have a Unified Parkinson's Disease Rating Scale (UPDRS) motor score of 30 or greater in their practically defined off condition at an initial evaluation. They will each show at least a 30% improvement in the UPDRS motor score from that of the practically defined off condition following a morning levodopa challenge.
3. At two preoperative evaluations the practically defined off UPDRS motor score should differ no more than +/- 15%
4. Subjects will be under the age of 70 years, either sex
5. Appropriate surgical candidate with no medical conditions that would interfere with long-term implantation of device and follow up
6. Patient must give signed informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned sample size: 8; UK sample size: 8
Participant exclusion criteria
1. Known current or past diabetes
2. Evidence of dementia, head trauma or medical conditions that may alter cerebral functioning
3. Past or present history of alcohol or substance abuse
4. Mini-mental state examination (MMSE) scores below 27 or above 30
5. Evidence of past or current serious psychopathology likely to affect the patients ability to benefit from surgery
Recruitment start date
22/10/2007
Recruitment end date
28/02/2011
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Frenchay Hospital
Bristol
BS16 1LE
United Kingdom
Sponsor information
Organisation
North Bristol NHS Trust (UK)
Sponsor details
Trust Headquarters
Beckspool Road
Frenchay
Bristol
BS16 1JE
United Kingdom
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Industry
Funder name
Medtronic PLC
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary